Study drug trial for mild to moderate plaque psoriasis
Part of Skin clinical trials.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older with plaque psoriasis on your skin (itchy/scaly “plaques”) bigger than 5 square centimeters
- Your psoriasis has been classified as mild to moderate, or moderate to severe, and has been that way for at least 1 year
- Your psoriasis is mostly plaque psoriasis (not other types like pustular or guttate), and hasn’t flared badly in the last 12 weeks
- You can attend study visits and follow study instructions, including avoiding certain sun exposure on the plaque areas
- If you can become pregnant, you agree to effective birth control during the study and for at least 3 months after the last dose
- You don’t have major uncontrolled medical problems (like serious heart/lung disease, uncontrolled blood pressure, recent stroke, or active infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called HSK44459 for people with moderate to severe plaque psoriasis. The hope is that the drug can reduce psoriasis symptoms and improve quality of life. Participation involves receiving the study drug and being monitored for safety and effectiveness.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial tests an experimental pill that may help clear psoriasis plaques. It is for people whose current topical treatments (creams or ointments) are not working well enough or cause side effects.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study tests an investigational medicine (HS-20118) for people with moderate-to-severe plaque psoriasis. The goal is to see if the drug can safely and effectively reduce psoriasis symptoms and improve quality of life.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.